Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 876 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... July 19, 2024 No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... June 15, 2022 Disparities in Cancer Care Between Citizens and Refugees in Lebanon March 23, 2021 FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab... August 5, 2026 Load more HOT NEWS How will new cancer medicines be approved in the future? Toothbrushes and ctDNA: Exciting early detection concepts from new teams formed... Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... Sustainability a major focus of our 17th year partnering with TK...
